Diazacycloalkanedione derivatives

US6642225B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Rainer Albert · Basel, CH
• Janet Dawson · Bennwil, CH
• Claus Ehrhardt · Lörrach, DE
• Sompong Wattanasin · Waltham, US
• Gabriele Weitz-Schmidt · Bad Krozingen, DE
• Karl Welzenbach · Basel, CH

Key dates

• Filing date: Oct 2, 2001
• Grant date: Nov 4, 2003
• Expiry date: Oct 2, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula I wherein R is carboxy, esterified carboxy or amidated carboxy;R1 and R3 are independently lower alkyl, (hydroxy, lower alkoxy, amino, acylamino, mono- or di-lower alkylamino or mercapto)-lower alkyl, lower alkyl-(thio, sulfinyl or sulfonyl)-lower alkyl, cycloalkyl, aryl, biaryl, (cycloalkyl, aryl or biaryl)-lower alkyl, or (carboxy, esterified carboxy or amidated carboxy)-lower alkyl;R2 is hydrogen, lower alkyl, cycloalkyl, aryl, biaryl, arylaminocarbonyl, or aryl-(oxy, thio or amino);n is 1 or 2;Y is lower-alkylene or lower alkenylene;and pharmaceutically acceptable salts thereof; which are useful as LFA-1 antagonists.